Plasminogen activator inhibitor type-2 in the lesional epidermis of lupus erythematosus

British Journal of Dermatology

Volumn 134, Issue 3, 1996, Pages 411-419

  Bechtel, M J ^a   Schaefer, B M ^a   Kramer, M D ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 2; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; LUPUS ERYTHEMATOSUS; PRIORITY JOURNAL; SKIN DEFECT;

EID: 0029914598     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1996.tb16223.x     Document Type: Article

References (37)

1. Jensen PJ, Baird J, Morioka S, Lessin S et al. Epidermal plasminogen activator is abnormal in cutaneous lesions. J Invest Dermatol 1988; 90: 777-82.
2. Baird J, Lazarus GS, Belin D, Vassalli J-D et al. mRNA for tissue-type plasminogen activator is present in lesional epidermis from patients with psoriasis, pemphigus, or bullous permphigoid, but is not detected in normal epidermis. J Invest Dermatol 1990; 95: 548-52.
3. Jensen P, John M, Baird J. Urokinase and tissue type plasminogen activators in human keratinocyte culture. Exp Cell Res 1990; 187: 162-9
4. Quax PHA, Boxman ILA, van Kesteren CAM et al. Plasminogen activators are involved in keratinocyte and fibroblast migration in wounded cultures in vitro. Fibrinolysis 1994; 8: 221-8.
5. Hashimoto K, Wun T-C, Baird J et al. Characterization of keratinocyte plasminogen activator inhibitors and demonstration of the prevention of pemphigus IgG-induced acantholysis by a purified plasminogen activator inhibitor. J Invest Dermatol 1989; 92: 310-15.
6. Hibino T, Izaki S, Ohkuma M et al. Epidermal plasminogen activator inhibitor (PAI) is immunologically identical to placental-type PAI-2. FEBS Lett 1988; 231: 202-6.
7. Lyons-Giordano B, Loskutoff D, Chen C-S et al. Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis. Histochemistry 1994; 101: 105-12.
8. Andreasen PA, George B, Lund LR et al. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 1990; 68: 1-19.
9. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-7.
10. Vassalli J-D, Sappino A-P, Belin D. The plasminogen activator/ plasmin system. J Clin Invest 1991; 88: 1067-72.
11. Jensen PJ, Baird J, Belin D et al. Tissue plasminogen activator in psoriasis. J Invest Dermatol 1990; 95: 13S-4S.
12. Sappino A-P, Belin D, Huarte J et al. Differential protease expression by cutaneous squamous and basal cell carcinoma. J Clin Invest 1991; 88: 1073-9.
13. Gissler HM, Rank R, Kramer MD. Immunohistochemical characterization of the plasminogen activator system in psoriatic epidermis. Br J Dermatol 1993; 128: 612-18.
14. Morioka S, Jensen PJ, Lazarus GS. Human epidermal plasminogen activator. Characterization, localization, and modulation. Exp Cell Res 1985; 161: 364-72.
15. Green H. Terminal differentiation of cultured human epidermal cells. Cell 1977; 11: 405-16.
16. Grondahl Hansen J, Lund LR, Ralfkiaer E et al. Urokinase- and tissue-type plasminogen activators in keratinocytes during wound re-epithelialization in vivo. J Invest Dermatol 1988; 90: 790-5.
17. Morioka S, Lazarus GS, Baird JL, Jensen PJ. Migrating keratinocytes express urokinase-type plasminogen activator. J Invest Dermatol 1987; 88: 418-23.
18. Hashimoto K, Shafran KM, Webber PS et al. Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells. A mechanism for the loss of epidermal cohesion and blister formation. J Exp Med 1983; 157: 259-72.
19. Morioka S, Lazarus GS, Jensen PJ. Involvement of urokinase-type plasminogen activator in acantholysis induced by pemphigus IgG. J Invest Dermatol 1987; 89: 474-7.
20. Grondahl-Hansen J, Nielsen LS, Kristensen P et al. Plasminogen activator in psoriatic scales is of the tissue-type PA as identified by monoclonal antibodies. Br J Dermatol 1985; 113: 257-63.
21. Grondahl-Hansen J, Ralfkiaer E, Nielsen LS et al. Immunohistochemical localization of urokinase- and tissue-type plasminogen activators in psoriatic skin. J Invest Dermatol 1987; 88: 28-32.
22. Chen C-S, Lyons-Giordano B, Lazarus GS, Jensen PJ. Differential expression of plasminogen activators and their inhibitors in an organotypic skin coculture system. J Cell Sci 1993; 106: 45-53.
23. Hashimoto K, Katayama I, Nishioka K. Tissue plasminogen activator inhibitor in the epidermis. Br J Dermatol 1985; 113: 523-7.
24. de Jong EM, van Erp PE, Ruiter DJ, van de Kerkhof PC. Immunohistochemical detection of proliferation and differentiation in discoid lupus erythematosus. J Am Acad Dermatol 1991; 25: 1032-8.
25. Buessecker F, Reinartz J, Schirmer U, Kramer MD. Enzyme-linked immunosorbent assays for plasminogen activators. J Immunol Methods 1993; 162: 193-200.
26. Boukamp P, Petrusevska RT, Breitkreuz D et al. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 1988; 106: 761-71.
27. Laug WE, Cao XR, Yu YB et al. Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. Cancer Res 1993; 53: 6051-7.
28. Schäfer BM, Maier K, Eickhoff U et al. Plasminogen activation in healing human wounds. Am J Pathol 1994; 144: 1269-80.
29. Thorsen S, Philips M, Selmer J et al. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2. Eur J Biochem 1988; 175: 33-9.
30. Grinnell F. Wound repair, keratinocyte activation and integrin modulation. J Cell Sci 1992, 101: 1-5.
31. Jensen PH, Lorand L, Ebbesen P, Gliemann J. Type-2 plasminogen-activator inhibitor is a substrate for trophoblast transglutaminase and factor XIII. Eur J Biochem 1993; 214: 141-6.
32. Rice RH, Green H. Relation of protein synthesis and transglutaminase activity to formation of the cross-linked envelope during terminal differentiation of the cultured human epidermal keratinocyte. J Cell Biol 1978; 76: 705-11.
33. Watt FM, Phil D. Involucrin and other markers of keratinocyte terminal differentiation. J Invest Dermatol 1983; 81: 100-3.
34. Greenberg CS, Birckbichler PJ, Rice RH. Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB J 1991; 5: 3071-7.
35. Pytel BA, Peppel K, Baglioni C. Plasminogen activator inhibitor type-2 is a major protein induced in human flbroblasts and SK-MEL-109 melanoma cells by tumor necrosis factor. J Cell Physiol 1990; 144: 416-22.
36. Kumar S, Baglioni C. Protection from tumour necrosis factor-mediated cytolysis by over expression of plasminogen activator inhibitor type-2. J Biol Chem 1991; 266: 20960-4.
37. Haake AR, Polakowska RR. Cell death by apoptosis in epidermal biology. J Invest Dermatol 1993; 101: 107-12.